Back to results
US 8,476,069 B2Granted
Cells useful for immuno-based botulinum toxin serotype A activity assays
AssigneeAllergan, Inc.
InventorsHong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
Life of this patent
Estimating the term…
Abstract
The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
Claims5
An established single cell derived clonal cell line from a parental SiMa cell line DSMZ ACC 164 comprising cells susceptible to intoxication by botulinum toxin type A (BoNT/A),
- wherein the cells exhibit at least a 1.5-fold increase in mRNA expression levels after differentiation in the genes CD9, ENC1, Gβγ, GNAI1, GNG11, GNG12, GPSM2, ITGA6, JNK, KCNJ4, MSN, MYRIP, NXPH1, STK17A, TRAF4, TSPAN, TSPAN4 and VAV3 relative to the mRNA expression levels of each of these genes in cells from a 2D6 derived from the parental SiMa cell line DSMZ ACC 164;
- and,
- wherein the cells exhibit at least a 1.5-fold decrease in mRNA expression levels after differentiation in the genes CNGA3, HIST1H3E and PTGS1 as compared to the mRNA expression levels of each of these genes in cells from the 2D6 cell line;
- and,
- wherein the clonal cell line comprises cells susceptible to BoNT/A intoxication by about 100 pM or less of a BoNT/A.
2 more elements
Dependencies are inferred from the claim text.